By Denise Roland
LONDON-- AstraZeneca PLC on Friday reported a fall in
first-quarter revenue and profit as the company invests in new
drugs, while sales of its older blockbusters are eroded by cheaper
rivals.
The U.K.-based company said core net profit fell to $1.37
billion in the quarter ended March 31, 7% lower than a year
earlier, or 3% at constant exchange rates.
Revenue from product sales fell to $5.75 billion--a drop of 10%,
or 3% at constant exchange rates. Analysts surveyed by Dow Jones
forecast core net profit of $1.37 billion and revenue of $5.68
billion. Total revenue, which for the first time included income
from licensing deals, increased 1% to $6.06 billion at constant
exchange rates.
But the company was eager to direct the focus onto its pipeline
of new drugs, especially those in a hot research area known as
immuno-oncology, which looks at strengthening the body's own immune
defenses to fight cancer.
AstraZeneca reported two new licensing deals in this area, both
aimed at broadening the applications of immuno-oncology drugs in
its own pipeline.
It will pay French biotech Innate Pharma SA up to $1.28 billion
to exclusively co-develop and commercialize a drug known as IP2201
as a combination therapy with its own drugs. It will also pay
royalties on eventual sales.
Astra has also done a deal with Celgene Corporation, whereby
Celgene will pay the U.K.-based drug maker $450 million to develop
one of its immuno-oncology treatments in a range of blood cancers.
The drug, known as MEDI4736, is being developed for lung and head
and neck cancer by AstraZeneca.
Pascal Soriot, chief executive, described the results as
"encouraging" and maintained full-year guidance of a mid-single
digit percentage decline in revenue and a low-single digit increase
in core earnings per share. He noted that the company's oncology
research program was now running 72 trials, including 31 in
immuno-oncology.
He also highlighted the strong performance of the company's
so-called "growth platforms"--the products or regions it is betting
on as the main sources of future revenue. These areas, spanning
heart drug Brilinta, lung drugs, diabetes, cancer, emerging markets
and Japan, accounted for 56% of total revenue.
Access Investor Kit for Celgene Corp.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US1510201049
Subscribe to WSJ: http://online.wsj.com?mod=djnwires